Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
PLoS One
2014 Dec 01;912:e116001. doi: 10.1371/journal.pone.0116001.
Show Gene links
Show Anatomy links
Acquisition of anoikis resistance up-regulates syndecan-4 expression in endothelial cells.
Carneiro BR
,
Pernambuco Filho PC
,
Mesquita AP
,
da Silva DS
,
Pinhal MA
,
Nader HB
,
Lopes CC
.
???displayArticle.abstract???
Anoikis is a programmed cell death induced upon cell detachment from extracellular matrix, behaving as a critical mechanism in preventing adherent-independent cell growth and attachment to an inappropriate matrix, thus avoiding colonization of distant organs. Cell adhesion plays an important role in neoplastic transformation. Tumors produce several molecules that facilitate their proliferation, invasion and maintenance, especially proteoglycans. The syndecan-4, a heparan sulfate proteoglycan, can act as a co-receptor of growth factors and proteins of the extracellular matrix by increasing the affinity of adhesion molecules to their specific receptors. It participates together with integrins in cell adhesion at focal contacts connecting the extracellular matrix to the cytoskeleton. Changes in the expression of syndecan-4 have been observed in tumor cells, indicating its involvement in cancer. This study investigates the role of syndecan-4 in the process of anoikis and cell transformation. Endothelial cells were submitted to sequential cycles of forced anchorage impediment and distinct lineages were obtained. Anoikis-resistant endothelial cells display morphological alterations, high rate of proliferation, poor adhesion to fibronectin, laminin and collagen IV and deregulation of the cell cycle, becoming less serum-dependent. Furthermore, anoikis-resistant cell lines display a high invasive potential and a low rate of apoptosis. This is accompanied by an increase in the levels of heparan sulfate and chondroitin sulfate as well as by changes in the expression of syndecan-4 and heparanase. These results indicate that syndecan-4 plays a important role in acquisition of anoikis resistance and that the conferral of anoikis resistance may suffice to transform endothelial cells.
???displayArticle.pubmedLink???
25549223
???displayArticle.pmcLink???PMC4280138 ???displayArticle.link???PLoS One
Figure 1. Morphologic characteristics and integrin β5 expression of EC-derived cell lines.(A) Parental (EC), EJ-ras transfected endothelial cells (EJ-ras EC), and anoikis-resistant endothelial cells (Adh1−EC and Adh2−EC) were maintained in culture for 7 days and photographed under a Nikon phase contrast microscope. Bar = 100 µm. (B) Immunofluorescent analysis of F-actin and integrin β5 in EC, EJ-ras EC, Adh1−EC and Adh2−EC cells. Actin filaments were stained with Alexa Fluor-488 phalloidin (green) and integrin β5 was stained with anti-integrin β5 antibody followed by secondary Hilyte Fluor-594-labelled antibody (red). Nucleus stained with DAPI (blue). Scale bar: 50 µm. (C) The protein expression levels of integrin β5 were assessed by western blot analysis. GAPDH is shown as a protein loading control. Histogram depicting integrin β5 protein levels normalized to GAPDH. (D) Flow cytometry analysis for cell surface presentation of integrin β5 in EC, EJ-ras EC, Adh1−EC and Adh2−EC cells. Filled histogram, cells treated with anti-integrin β5 and secondary antibody; opened histogram, cells treated only with secondary antibody. In B, C and D, two independent experiments were performed in duplicates. The bars represent the standard error.
Figure 2. Proliferation and cell cycle of EC-derived cell lines.(A) Growth curves of EC, EJ-ras transfected cells (EJ-ras EC), and EC anoikis resistant (Adh1−EC and Adh2−EC). (B) BrdU incorporation for 20 h. Serum-starved EC, EJ-ras-transfected cells (EJ-ras EC) and EC anoikis resistant (Adh1−EC and Adh2−EC) were serum-starved, as described in Methods, and stimulated to proliferate by the addition of 10% FCS. (C) Cell cycle distribution of EC, EJ-ras transfected cells (EJ-ras EC), and EC anoikis resistant (Adh1−EC and Adh2−EC). Histograms show the proportion of cells at different stages in the cell cycle (DNA content of propidium iodide–stained nuclei) analyzed by flow cytometry. ABS: absorbance. All experiments were repeated three times. The bars represent the standard error. * P≤0.05.
Figure 3. Adhesion rate of EC-derived cell lines.(A), (B) and (C) Assay adhesion of parental (EC), EJ-ras transfected endothelial cells (EJ-ras EC), and anoikis-resistant endothelial cells (Adh1−EC and Adh2−EC) on fibronectin, laminin, and collagen IV, respectively. ABS: absorbance. The experiments were performed in triplicates and repeated three times. The bars represent the standard error. * P≤0.05.
Figure 4. Invasion capacity and percentage of apoptosis in EC-derived cell lines.(A) Values of relative invasiveness of EJ-ras EC, Adh1−EC and Adh2−EC cells normalized with those of EC cells (100%). Invasion activity of EC-derived cell lines was analyzed by using a Transwell coated with ECL cell attachment matrix as described in Methods. (B) Percentage of apoptotic cells detected by Annexin V-FITIC/PI double staining method in EC, EJ-ras transfected cells (EJ-ras EC), and EC anoikis resistant (Adh1vEC and Adh2−EC) cells. All experiments were repeated three times. The bars represent the standard error. * P≤0.05.
Figure 5. [35S] sulfated glycosaminoglycans synthesized by EC, EJ-ras EC, Adh1−EC and Adh2−EC cells.(A) Endothelial cells were exposed to [35S]sulfate for 18 h. The radioactive glycosaminoglycan-free chains were prepared, from both cells and conditioned medium, by incubation with proteolytic enzyme. Aliquots were subjected to electrophoresis for 60 min in 0.6% agarose (0.05 M 1,3-diaminopropane-acetate buffer pH 9.0) [38], [39]. The radioactive compounds were located in the gels, as described in Methods. CS: chondroitin sulfate; DS: dermatan sulfate; HS: heparan sulfate; OR: origin. (B) Quantification of the experiment shown in A. For further details, see Methods. The experiments were performed in duplicates and repeated three times. EC: parental endothelial cells; EJ-ras EC: EJ-ras transfected endothelial cells; Adh1−EC and Adh2−EC: anoikis-resistant endothelial cells. The bars represent the standard error. * P≤0.05.
Figure 6. Expression of syndecan-4 and heparanase in EC, EJ-ras EC, Adh1-EC and Adh2-EC cells.(A) Representative RT-PCR products fractionated in 1% agarose gel electrophoresis and stained with ethidium bromide, showing bands of the expected sizes. (B) Expression of syndecan-4 detected by RT-qPCR. GAPDH was used as a loading control. (C) The protein expression levels of syndecan-4 were assessed by western blot analysis. GAPDH is shown as a protein loading control. Histogram depicting syndecan-4 protein levels normalized to GAPDH. (D) Flow cytometry analysis for cell surface presentation of syndecan-4 in EC, EJ-ras EC, Adh1-EC and Adh2-EC cells. Filled histogram, cells treated with anti-syndecan-4 and secondary antibody; opened histogram, cells treated only with secondary antibody. (E) Expression of heparanase detected by RT-qPCR. GAPDH was used as a loading control. In A, B and E, the experiments were repeated four times. In C and D two independent experiments were performed in duplicates. EC: parental endothelial cells; EJ-ras EC: EJ-ras transfected endothelial cells; Adh1-EC and Adh2-EC: anoikis-resistant endothelial cells. The bars represent the standard error. * P≤0.05.
Baciu,
Protein kinase C regulates the recruitment of syndecan-4 into focal contacts.
1995, Pubmed
Baciu,
Protein kinase C regulates the recruitment of syndecan-4 into focal contacts.
1995,
Pubmed
Batista,
Heparanase expression and glycosaminoglycans profile in renal cell carcinoma.
2012,
Pubmed
Beauvais,
Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells.
2003,
Pubmed
Beauvais,
Syndecans in tumor cell adhesion and signaling.
2004,
Pubmed
Bernfield,
Functions of cell surface heparan sulfate proteoglycans.
1999,
Pubmed
Bernfield,
Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans.
1992,
Pubmed
Bianchi-Smiraglia,
Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways.
2013,
Pubmed
Bissell,
Putting tumours in context.
2001,
Pubmed
Buonassisi,
Hormone and neurotransmitter receptors in an established vascular endothelial cell line.
1976,
Pubmed
Carey,
Syndecans: multifunctional cell-surface co-receptors.
1997,
Pubmed
Caseli,
Probing the interaction between heparan sulfate proteoglycan with biologically relevant molecules in mimetic models for cell membranes: a Langmuir film study.
2012,
Pubmed
,
Echinobase
Castellot,
Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells.
1984,
Pubmed
Chiarugi,
From anchorage dependent proliferation to survival: lessons from redox signalling.
2008,
Pubmed
Chiarugi,
Anoikis: a necessary death program for anchorage-dependent cells.
2008,
Pubmed
Chiodoni,
Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis.
2010,
Pubmed
Choi,
Syndecans as cell surface receptors: Unique structure equates with functional diversity.
2011,
Pubmed
Clasper,
Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action.
1999,
Pubmed
Coombe,
Heparan sulfate-protein interactions: therapeutic potential through structure-function insights.
2005,
Pubmed
Couchman,
Transmembrane signaling proteoglycans.
2010,
Pubmed
Couchman,
Syndecans: proteoglycan regulators of cell-surface microdomains?
2003,
Pubmed
Dietrich,
Cell recognition and adhesiveness: a possible biological role for the sulfated mucopolysaccharides.
1977,
Pubmed
Dietrich,
Structural differences of heparan sulfates according to the tissue and species of origin.
1983,
Pubmed
Dietrich,
A model for cell-cell recognition and control of cell growth mediated by sulfated glycosaminoglycans.
1984,
Pubmed
Eble,
Integrins in cancer treatment.
2006,
Pubmed
Elkin,
Heparanase as mediator of angiogenesis: mode of action.
2001,
Pubmed
Erdem,
Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma.
2014,
Pubmed
Esko,
Molecular diversity of heparan sulfate.
2001,
Pubmed
Eswarakumar,
Cellular signaling by fibroblast growth factor receptors.
2005,
Pubmed
Fiore,
Cellular specificity for the activation of fibroblast growth factor-2 by heparan sulfate proteoglycan.
2001,
Pubmed
Fjeldstad,
Decreasing the metastatic potential in cancers--targeting the heparan sulfate proteoglycans.
2005,
Pubmed
Gambarini,
Mitogenic activity of acidic fibroblast growth factor is enhanced by highly sulfated oligosaccharides derived from heparin and heparan sulfate.
1993,
Pubmed
Gengrinovitch,
Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165.
1999,
Pubmed
Gilmore,
Anoikis.
2005,
Pubmed
Gulyás,
Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
2003,
Pubmed
Horowitz,
Fibroblast growth factor-specific modulation of cellular response by syndecan-4.
2002,
Pubmed
Hyatt,
Protein kinase C is localized in focal contacts of normal but not transformed fibroblasts.
1990,
Pubmed
Iozzo,
Matrix proteoglycans: from molecular design to cellular function.
1998,
Pubmed
Kjellén,
Proteoglycans: structures and interactions.
1991,
Pubmed
Kotsakis,
Tissue transglutaminase in tumour progression: friend or foe?
2007,
Pubmed
Kraemer,
Cell-cycle dependent desquamation of heparan sulfate from the cell surface.
1972,
Pubmed
Kram,
Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass.
2006,
Pubmed
Labropoulou,
Expression of syndecan-4 and correlation with metastatic potential in testicular germ cell tumours.
2013,
Pubmed
Lin,
Functions of heparan sulfate proteoglycans in cell signaling during development.
2004,
Pubmed
Liotta,
Anoikis: cancer and the homeless cell.
2004,
Pubmed
Liu,
Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans.
2002,
Pubmed
Lopes,
Specific structural features of syndecans and heparan sulfate chains are needed for cell signaling.
2006,
Pubmed
Lopes,
EJ-ras oncogene transfection of endothelial cells upregulates the expression of syndecan-4 and downregulates heparan sulfate sulfotransferases and epimerase.
2006,
Pubmed
Matsuda,
Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
2001,
Pubmed
Morgan,
Synergistic control of cell adhesion by integrins and syndecans.
2007,
Pubmed
Mundhenke,
Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas.
2002,
Pubmed
Na,
Syndecan-4 and fibronectin in osteosarcoma.
2012,
Pubmed
Nader,
Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan.
1987,
Pubmed
Nader,
Heparins and heparinoids: occurrence, structure and mechanism of antithrombotic and hemorrhagic activities.
2004,
Pubmed
Nader,
Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells.
1989,
Pubmed
Oba-Shinjo,
Melanocyte transformation associated with substrate adhesion impediment.
2006,
Pubmed
Oh,
Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C.
1997,
Pubmed
Oh,
Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C.
1997,
Pubmed
Pazos,
Putative role of heparan sulfate proteoglycan expression and shedding on the proliferation and survival of cells after photodynamic therapy.
2007,
Pubmed
Porcionatto,
Stimulation of heparan sulfate proteoglycan synthesis and secretion during G1 phase induced by growth factors and PMA.
1998,
Pubmed
Purushothaman,
Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.
2008,
Pubmed
Reddig,
Clinging to life: cell to matrix adhesion and cell survival.
2005,
Pubmed
Rennebeck,
Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?
2005,
Pubmed
Rosenberg,
Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?
1997,
Pubmed
Roskams,
Heparan sulphate proteoglycan expression in human primary liver tumours.
1998,
Pubmed
Sanderson,
Heparan sulfate proteoglycans in invasion and metastasis.
2001,
Pubmed
Sasisekharan,
Roles of heparan-sulphate glycosaminoglycans in cancer.
2002,
Pubmed
Sastry,
Integrin cytoplasmic domains: mediators of cytoskeletal linkages and extra- and intracellular initiated transmembrane signaling.
1993,
Pubmed
Shimazu,
Expression of syndecan-2, -4, and fibroblast growth factor receptor type 1 in human periodontal ligament fibroblasts and down-regulation of these membrane proteins during maturation in culture.
1999,
Pubmed
Stupack,
ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands.
2002,
Pubmed
Sudhalter,
Schwann cell heparan sulfate proteoglycans play a critical role in glial growth factor/neuregulin signaling.
1996,
Pubmed
Theodoro,
Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis.
2007,
Pubmed
Thompson,
Site-directed neovessel formation in vivo.
1988,
Pubmed
Valentijn,
Anoikis.
2004,
Pubmed
Vlodavsky,
Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis.
1999,
Pubmed
Vlodavsky,
Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis.
2001,
Pubmed
Wang,
Importance of syndecan-4 and syndecan -2 in osteoblast cell adhesion and survival mediated by a tissue transglutaminase-fibronectin complex.
2011,
Pubmed
Wang,
Molecular signaling regulating anchorage-independent growth of cancer cells.
2004,
Pubmed
Wiedłocha,
Signaling, internalization, and intracellular activity of fibroblast growth factor.
2004,
Pubmed
Woods,
Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component.
1994,
Pubmed
Woods,
Syndecan-4 and focal adhesion function.
2001,
Pubmed
Yayon,
Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.
1991,
Pubmed
Zcharia,
Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior.
2004,
Pubmed
Zhang,
Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo.
2003,
Pubmed